Tobacco company Philip Morris International (NYSE:PM) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 7.1% year on year to $10.14 billion. Its non-GAAP profit of $1.91 per share was 2.8% above analysts’ consensus estimates.
Chamath Palihapitiya endorsed Bill Pulte as the next Federal Reserve chair, praising his housing expertise and Trump alignment amid rising speculation over Jerome Powell's potential ouster.
Economist Mohamed El-Erian is shedding light on the dislocation in the financial markets, drawing sharp contrasts between a booming tech sector and a weakening sovereign backdrop.
The stock fell 10.8% on Tuesday, its largest single-day drop since late 2021, after it booked charges, primarily related to a classified program within its aeronautics unit.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Businesses with strong free cash flow tend to be more adaptable and resilient.
Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 13.6%. This performance is a stark contrast from the S&P 500’s 3.1% gain.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Nvidia CEO Jensen Huang admits to working 24/7, even while watching movies. His intense work ethic has propelled the company to a $4 trillion valuation.
Baird’s Tristan Gerra attributed the post-market weakness to investors' concerns about a change in the management tone on the call, combined with a sequentially flattish gross margin guidance.
Republican Senators released a discussion draft for the cryptocurrency market structure legislation on Tuesday, building on the recent passage of the CLARITY Act in the House of Representatives.
Over the past six months, BlackLine’s stock price fell to $56.82. Shareholders have lost 6% of their capital, which is disappointing considering the S&P 500 has climbed by 3.1%. This may have investors wondering how to approach the situation.
Methode Electronics has gotten torched over the last six months - since January 2025, its stock price has dropped 48.9% to $6.65 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Curtiss-Wright currently trades at $474.48 and has been a dream stock for shareholders. It’s returned 416% since July 2020, blowing past the S&P 500’s 94.7% gain. The company has also beaten the index over the past six months as its stock price is up 23.5% thanks to its solid quarterly results.
Allegro MicroSystems has been on fire lately. In the past six months alone, the company’s stock price has rocketed 40.4%, reaching $35.02 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Over the past six months, Campbell’s stock price fell to $32.23. Shareholders have lost 16.5% of their capital, which is disappointing considering the S&P 500 has climbed by 3.1%. This may have investors wondering how to approach the situation.
What a brutal six months it’s been for 8x8. The stock has dropped 27% and now trades at $2, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Over the past six months, DaVita’s shares (currently trading at $146.05) have posted a disappointing 14% loss, well below the S&P 500’s 3.1% gain. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
